Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 659 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR 2026 ESMO TAT Honorary Award Recipient Announced February 3, 2026 Cancer, COVID-19, and Competing Threats to Indigenous Health July 20, 2020 Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... July 5, 2018 FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma December 5, 2025 Load more HOT NEWS Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and... Amivantamab Demonstrates Robust Efficacy in Patients with EGFR Exon 20 Insertion-Mutated... John Cena Set The Record For Most Make-A-Wish Visits And He... Workout Wednesday – Leg Stretches Part 1
